SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
A Systematic Review of Chronic Pulmonary Aspergillosis Among Patients Treated for Pulmonary Tuberculosis.
Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.MedComm · 2026Review
- Invasive Pulmonary Aspergillosis Presenting as a Giant Abscess in a Post-tuberculosis Destroyed Lung: A Case Report.Cureus · 2026Article
- Reappraising TB preventive treatment in India: programmatic and ethical implications of subclinical tuberculosis in household contacts.The Lancet regional health. Southeast Asia · 2026Review
- Clinical Features and Mortality of Chronic Pulmonary Aspergillosis in Brazil: a Multicenter Cohort Study.Open forum infectious diseases · 2026Article
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
- Primary tuberculous mycobacterial granulomas provide a niche for superinfecting Mycobacterium abscessus.Nature communications · 2025Article
- Diagnostic performance ofJournal of thoracic disease · 2025Article
- Cavitary pulmonary tuberculosis withFrontiers in medicine · 2025Article
- Development of a Predictive Risk Model for Recurrence of Chronic Pulmonary Aspergillosis in Post-Tuberculosis Patients: A Retrospective Observational Study.International journal of general medicine · 2025Article
- Occurrence of Chronic Pulmonary Aspergillosis in Pulmonary Tuberculosis: A Hospital-Based Cross-Sectional Study.Nigerian medical journal : journal of the Nigeria Medical AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTuberculosis (TB) is a major global health concern, with long-term complications persisting even after successful treatment. Chronic pulmonary aspergillosis (CPA) is a progressive fungal disease that frequently develops in TB survivors, contributing to post-TB lung disease. The true burden of CPA among patients with TB remains unclear due to diagnostic challenges and limited data. We aimed to estimate the prevalence of CPA among patients with prior or concurrent TB.
methodsWe conducted a systematic search in PubMed, Cochrane Library, Web of Science, and Science Direct through 10 January 2025. Eligible cohort and cross-sectional studies reported CPA prevalence in patients diagnosed with TB based on clinical symptoms, radiographic abnormalities, and microbiological evidence. Three reviewers screened 1575 unique studies, assessed 118 full texts, and included 22 studies (2884 patients). We conducted a meta-analysis using a random-effects model to estimate pooled CPA prevalence, with subgroup and meta-regression analyses exploring factors influencing CPA burden.
resultsCPA prevalence varied by timing of assessment and symptom status. Among all patients with TB, CPA prevalence was 9% (95% confidence interval [CI]: 6%-12%) during treatment and 13% (95% CI: 6%-27%) posttreatment. Among patients with persistent respiratory symptoms, CPA prevalence was 20% during treatment and 48% (95% CI: 36%-61%) posttreatment. Meta-regression identified symptom status and timing of CPA assessment as significant predictors of CPA prevalence.
conclusionsThe high CPA burden among TB survivors, particularly those with persistent symptoms, underscores the need for routine CPA screening in TB programs. Early detection and targeted interventions could reduce respiratory complications and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.